Literature DB >> 12963495

Pharmacological and biochemical characterization of the beta-adrenergic signal transduction pathway in different segments of the respiratory tract.

Getu Abraham1, Claudia Kottke, Stefan Dhein, Fritz Rupert Ungemach.   

Abstract

Although in the respiratory system there is great therapeutic interest in manipulating and understanding the beta-adrenoceptor-G-protein-adenylate cyclase (AC) signal transduction pathway, little is known on segmental differences among lung, bronchus, and trachea with regard to the receptor concentration and interaction to G-proteins and coupling to AC. In this study, patterns of distribution and absolute quantities of beta-adrenoceptor subtypes beta(1) and beta(2) were determined in membranes of equine lung parenchyma, bronchial and tracheal epithelium with the underlying smooth muscle by saturation and competition binding assays using the radioligand (-)-[125I]-iodocyanopindolol (ICYP). Additionally, the functional coupling of beta-adrenoceptors to G-proteins (assessed by beta-agonist competition binding in the presence and absence of GTP) as well as the coupling efficiency and biochemical activities of AC was investigated in each region. The specific ICYP binding was rapid, reversible, saturable with time and of high affinity. The radioligand binding identified more total beta-adrenoceptors in the lung than in bronchus or trachea (428+/-19, 162.4+/-4.8, 75.6+/-1.2 fmol/mg protein, respectively) with about 40% of receptors in the high affinity state. The beta(2)-adrenoceptor subtype predominated in all segments (approximately 74-80%), as the highly selective beta(2)-adrenoceptor antagonist ICI 118,551 was about 10,000 times more potent in inhibiting ICYP binding than was the beta(1)-selective adrenoceptor antagonist CGP 20712A, and beta-adrenoceptor agonists inhibited ICYP binding with an order of potency: (-)-isoprenaline>(-)-adrenaline>(-)-noradrenaline. The dissociation constant (K(d)) was higher in the trachea than in bronchus or lung (13.0+/-0.9 pM vs. 20.0+/-2.3 pM vs. 30.8+/-4.4 pM, P<0.05, respectively). The beta(2)-adrenoceptor-mediated AC response was tissue-dependent; stimulants acting on beta-adrenoceptor (isoproterenol), G-protein (GTP, NaF) and AC (forskolin, Mn(2+)) enhanced AC responses in all three regions, but the AC activity was higher in tracheal crude membranes than in bronchus or lung (trachea>>>bronchus>lung), hence, the number of beta(2)-adrenoceptors correlated inversely with the amount of AC. We conclude that (1) the stoichiometry of components within the pulmonary beta-adrenoceptor-G-protein complex is segment-dependent, and (2) the receptor number or AC activity is possibly the rate-limiting factor in the beta-adrenoceptor-G-protein-AC-mediated physiological responses. Thus, it is speculated that this could have important therapeutic consequences in beta-adrenoceptor agonist-induced receptor regulation in bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963495     DOI: 10.1016/s0006-2952(03)00460-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways.

Authors:  T Ikeda; A S M Anisuzzaman; H Yoshiki; M Sasaki; T Koshiji; J Uwada; A Nishimune; H Itoh; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  Segment-dependent expression of muscarinic acetylcholine receptors and G-protein coupling in the equine respiratory tract.

Authors:  G Abraham; C Kottke; H Ammer; S Dhein; F R Ungemach
Journal:  Vet Res Commun       Date:  2006-12-15       Impact factor: 2.459

3.  A system for screening agonists targeting beta2-adrenoceptor from Chinese medicinal herbs.

Authors:  Hui Wang; Shi-you Li; Chuan-ke Zhao; Xin Zeng
Journal:  J Zhejiang Univ Sci B       Date:  2009-04       Impact factor: 3.066

4.  Isolation and culture of primary equine tracheal epithelial cells.

Authors:  Workineh Shibeshi; Getu Abraham; Carsten Kneuer; Christin Ellenberger; Johannes Seeger; Heinz-Adolf Schoon; Fritz R Ungemach
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-07-02       Impact factor: 2.416

5.  Alpha1-and beta2-adrenoceptors in the human liver with mass-forming intrahepatic cholangiocarcinoma: density and coupling to adenylate cyclase and phospholipase C.

Authors:  W T Kassahun; B Günl; A Tannapfel; F R Ungemach; J Hauss; G Abraham
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-11-15       Impact factor: 3.000

6.  In vitro and in silico studies of 8(17),12E,14-labdatrien-18-oic acid in airways smooth muscle relaxation: new molecular insights about its mechanism of action.

Authors:  Edilson B Alencar Filho; Luciano A A Ribeiro; Thiego G C Carvalho; Fabrício S Silva; Luiz Antonio M S Duarte-Filho; Euzébio G Barbosa; Pedro M N Menezes; Josean F Tavares; Marcelo S da Silva; Bagnólia A Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-18       Impact factor: 3.000

7.  Adaptation to excess acetylcholine by downregulation of adrenoceptors and muscarinic receptors in lungs of acetylcholinesterase knockout mice.

Authors:  Jaromir Myslivecek; Ellen G Duysen; Oksana Lockridge
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-06       Impact factor: 3.000

8.  Inhibitory pathways in the circular muscle of rat jejunum.

Authors:  Gwen Vanneste; Patrick Robberecht; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

9.  Quantification of beta adrenergic receptor subtypes in beta-arrestin knockout mouse airways.

Authors:  Akhil Hegde; Ryan T Strachan; Julia K L Walker
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

10.  Evaluation of spirometry values in relation to beta-2-adrenergic receptor gene polymorphism.

Authors:  Iwona Poziomkowska-Gesicka; E Dzieciolowska-Baran; A Gawlikowska-Sroka; D Slowik-Zylka; T Sroczynski
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.